Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
about
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivoAnnexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradationRegulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)The PCSK9 decadeLipid nanoparticles for targeted siRNA delivery - going from bench to bedsideNew developments in atherosclerosis: clinical potential of PCSK9 inhibitionHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorPCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signalingIDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functionsIdentifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene.The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.Spatio-temporal dependence of the signaling response in immune-receptor trafficking networks regulated by cell density: a theoretical model.PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Local effects of human PCSK9 on the atherosclerotic lesion.Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)PCSK9 prosegment chimera as novel inhibitors of LDLR degradation.Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function.An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genesAmyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice.Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liverPolydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)Treadmill Exercise Training Modulates Hepatic Cholesterol Metabolism and Circulating PCSK9 Concentration in High-Fat-Fed Mice.Combined Effects of Rosuvastatin and Exercise on Gene Expression of Key Molecules Involved in Cholesterol Metabolism in Ovariectomized RatsSerum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents.PCSK9: an emerging target for treatment of hypercholesterolemia.The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.On the cutting edge of proprotein convertase pharmacology: from molecular concepts to clinical applications.
P2860
Q21136366-B491DD9A-49DB-42CE-AD7A-0867E5F6C91EQ24294486-C71F1840-0AE8-4FF1-8493-D5D93E0C79F9Q24312859-3E7E3CD5-93BF-4EF8-91D7-1408F7EE7ACCQ24615397-5228D10A-E672-477A-B5AF-B6928578507DQ26741449-2D2C9F45-354C-4BCC-B97A-B22C0422B7E0Q26783407-6998F07F-8005-4776-AC66-78F4A43E4D7BQ26786549-CC7B959D-0A33-4639-9869-405FAEBE1412Q27009477-608A59E2-C564-459F-9078-16834589BEF3Q27339783-91802A93-E678-4031-95B6-092DE9C88DDBQ28258969-4BFAC187-3A47-4F9F-A43D-BB0DF29BD73AQ28586625-405BD010-D1F1-4800-8FA4-663A2C1EE17FQ30538763-99AEF464-382B-4ED4-87B3-392B0EFEA022Q30541820-9C4E6C53-68FD-4973-9289-A621C69E1032Q33732407-AE439684-8E16-4C85-9A68-0F27A4668429Q33924208-71F85A8C-82F8-4C75-9357-3D259B97B8C3Q33971107-B11F64A7-BC8D-4814-8CD6-BD207AC2532FQ33994685-4762CECB-FA14-4089-B8AA-D976B484446DQ34355679-EF3E9EFF-F6EC-42F0-A9E4-F2571CC7293BQ34375398-A98A8ACB-D9B0-494D-B1F9-5CA65CA1B09BQ34430377-CC929118-9881-46F6-8784-4DCC1AEFEBFCQ34433146-50DBDAA6-F1DB-46E7-A63E-99215C39EBAAQ34492178-1AA0CE50-B6B2-4D05-AD85-5808E10E6F59Q34536594-69CD1A83-B371-4711-A133-020049F49967Q34723257-28087250-EA1D-4AAB-910D-6E38C2025581Q34951227-2973E991-A699-4D16-B5A6-DDCB8B86FC0EQ35096270-C3A9F4E4-0B37-4F23-982C-1F612017A61AQ35612555-EE1E8804-A187-468E-8104-1B8DF0F60640Q35767551-209BDC3A-1005-4F36-AA81-5A9B889B903DQ35883857-E9633FFF-1432-41E5-B9CA-6AF17A5F5FC5Q36197840-0D000F73-33F2-49EE-8125-5942550B117BQ36281706-49176D65-AD44-468C-8AEC-77BE1546EAF3Q36520700-E45A0D2B-B9B8-430A-8D4A-D6E8F03396C4Q36529674-8C14005D-4720-432F-B8A2-26FA9BF39A91Q36990445-6EA061A9-0824-48CB-898A-AE36C646436AQ37115391-11733ABC-E482-4A9D-B06D-6FC10F8B459CQ37250324-DB676F1B-26B2-443F-BDBE-42495202B358Q37789741-9F235814-A806-4017-9565-FB40340A5CADQ37825903-628AAEA2-0ADE-450C-A5EB-E3E047B9C5F5Q37880856-C3A094AA-F5E5-4E4C-9B6C-E2CFE0FF1761Q37981645-96D65DA6-2EBD-40E3-B0FD-911681E62E3B
P2860
Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Dissection of the endogenous c ...... ce for an intracellular route.
@en
Dissection of the endogenous c ...... ce for an intracellular route.
@nl
type
label
Dissection of the endogenous c ...... ce for an intracellular route.
@en
Dissection of the endogenous c ...... ce for an intracellular route.
@nl
prefLabel
Dissection of the endogenous c ...... ce for an intracellular route.
@en
Dissection of the endogenous c ...... ce for an intracellular route.
@nl
P2093
P2860
P356
P1476
Dissection of the endogenous c ...... ce for an intracellular route.
@en
P2093
Franck J Duclos
Gaetan Mayer
Marie-Claude Asselin
Mark Witmer
Peter S McPherson
Rex Parker
Robert Day
Roxane Desjardins
Steve Poirier
P2860
P304
28856-28864
P356
10.1074/JBC.M109.037085
P407
P577
2009-07-27T00:00:00Z